رادار التجارب AI

دعونا نناقش ونستكشف التجارب السريرية مع هالوزيم ثيرابيوتيكس بصفتها الراعي الرئيسي أو الشريك.

يمكنني مساعدتك على فهم الحالات الصحية والعلاجات والعثور على التجارب السريرية القريبة.
أداة البحث لدينا تدعم اللغة الإنجليزية فقط. للبحث والمناقشة بلغات أخرى، استخدم 'رادار التجارب AI' أعلاه أو حدد عوامل التصفية الخاصة بالحالة والموقع أدناه.
٤٣ التجارب السريرية
 
الجنس
الكل
×
 
عنوان الدراسة
الحالة
MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma NCT04134468
مسحوب
Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC) NCT03979066
متوقف نهائيًاالنتائج المنشورة
A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20) (HALO-117-406) NCT03662334
مكتملالنتائج المنشورة
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) NCT03281369
مكتمل
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma NCT03267940
متوقف نهائيًاالنتائج المنشورة
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma NCT02921022
نشط (لا يقبل مشاركين جدد)
Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) NCT02753595
متوقف نهائيًاالنتائج المنشورة
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma NCT02715804
متوقف نهائيًاالنتائج المنشورة
Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase NCT02667223
متوقف نهائيًا
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors NCT02563548
مكتملالنتائج المنشورة
A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC (PRIMAL) NCT02346370
متوقف نهائيًاالنتائج المنشورة
S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer NCT01959139
مكتملالنتائج المنشورة
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) NCT01848990
مكتملالنتائج المنشورة
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer NCT01839487
مكتملالنتائج المنشورة
Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers NCT01572012
مكتمل
Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase NCT01526733
مكتملالنتائج المنشورة
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer NCT01453153
مكتملالنتائج المنشورة
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase NCT01426763
مكتملالنتائج المنشورة
Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM) NCT01275131
مكتملالنتائج المنشورة
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus NCT01194258
مكتملالنتائج المنشورة
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus NCT01194245
مكتملالنتائج المنشورة
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors NCT01170897
مكتمل
Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED) (INFUSE-TM) NCT01120431
مسحوب
Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A) NCT01116102
متوقف نهائيًاالنتائج المنشورة
A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone NCT00979875
مكتملالنتائج المنشورة
Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM) NCT00916357
مكتملالنتائج المنشورة
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus NCT00883558
مكتملالنتائج المنشورة
Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone NCT00862849
مكتملالنتائج المنشورة
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors NCT00834704
مكتمل
Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone NCT00807963
مكتمل
Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT) NCT00807885
مكتملالنتائج المنشورة
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20 NCT00803972
مكتمل
Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer (IPOP) NCT00782587
مكتمل
Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus NCT00774800
مكتملالنتائج المنشورة
Subcutaneous Rehydration Compared to Intravenous Rehydration (PEDs-II) NCT00773175
مكتملالنتائج المنشورة
Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex) (INFUSE-NSLR) NCT00656370
مكتملالنتائج المنشورة
INFUSE Morphine Study NCT00593281
مكتمل
Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration (INFUSE-Cftrx) NCT00493220
مكتملالنتائج المنشورة
Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children (INFUSE-PR) NCT00477152
مكتملالنتائج المنشورة
A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase NCT00435604
مكتمل
Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase NCT00369187
مكتمل
Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer NCT00318643
مكتملالنتائج المنشورة
A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects NCT00311519
مكتمل